Ehrlich P (1906) Collected studies on immunity. J Wiley & Sons, New York

Google Scholar 

Phase II (1994) Results using a new antibody in the treatment of lymphoma. Oncol (Williston Park) 8(12):84

Google Scholar 

Anderson DR, Grillo-López A, Varns C, Chambers KS, Hanna N (1997) Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin’s B-cell lymphoma. Biochem Soc Trans 25(2):705–708. https://doi.org/10.1042/bst0250705

Article  CAS  PubMed  Google Scholar 

Ruste V, Goldschmidt V, Laparra A, Messayke S, Danlos FX, Romano-Martin P et al (2021) The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry. Eur J Cancer.158:217– 24. https://doi.org/10.1016/j.ejca.2021.08.048

Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455–2465. https://doi.org/10.1056/NEJMoa1200694

Article  PubMed Central  CAS  PubMed  Google Scholar 

Callahan MK, Wolchok JD (2013) At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 94(1):41–53. https://doi.org/10.1189/jlb.1212631

Article  PubMed Central  CAS  PubMed  Google Scholar 

Patrinely JR Jr., Johnson R, Lawless AR, Bhave P, Sawyers A, Dimitrova M et al (2021) Chronic Immune-Related adverse events following adjuvant Anti-PD-1 therapy for High-risk resected melanoma. JAMA Oncol 7(5):744–748. https://doi.org/10.1001/jamaoncol.2021.0051

Article  PubMed  Google Scholar 

El Osta B, Hu F, Sadek R, Chintalapally R, Tang SC (2017) Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol 119:1–12. https://doi.org/10.1016/j.critrevonc.2017.09.002

Article  CAS  PubMed  Google Scholar 

Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE et al (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and Meta-analysis. JAMA Oncol 4(2):173–182. https://doi.org/10.1001/jamaoncol.2017.3064

Article  PubMed  Google Scholar 

Elshimy GRR, Akturk HK et al Immune Checkpoint Inhibitors Related Endocrine Adverse Events. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.: [Updated 2022 Jan 21]

Sznol M, Postow MA, Davies MJ, Pavlick AC, Plimack ER, Shaheen M et al (2017) Endocrine-related adverse events associated with immune checkpoint Blockade and expert insights on their management. Cancer Treat Rev 58:70–76. https://doi.org/10.1016/j.ctrv.2017.06.002

Article  CAS  PubMed  Google Scholar 

de Filette J, Andreescu CE, Cools F, Bravenboer B, Velkeniers B (2019) A systematic review and Meta-Analysis of Endocrine-Related adverse events associated with immune checkpoint inhibitors. Horm Metab Res 51(3):145–156. https://doi.org/10.1055/a-0843-3366

Article  CAS  PubMed  Google Scholar 

Byun DJ, Wolchok JD, Rosenberg LM, Girotra M (2017) Cancer immunotherapy - immune checkpoint Blockade and associated endocrinopathies. Nat Rev Endocrinol 13(4):195–207. https://doi.org/10.1038/nrendo.2016.205

Article  PubMed Central  CAS  PubMed  Google Scholar 

Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA (2014) Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 21(2):371–381. https://doi.org/10.1530/erc-13-0499

Article  PubMed Central  CAS  PubMed  Google Scholar 

Frasca F, Piticchio T, Le Moli R, Malaguarnera R, Campennì A, Cannavò S et al (2021) Recent insights into the pathogenesis of autoimmune hypophysitis. Expert Rev Clin Immunol 17(11):1175–1185. https://doi.org/10.1080/1744666x.2021.1974297

Article  CAS  PubMed  Google Scholar 

Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P (2014) Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 6(230):230ra45. https://doi.org/10.1126/scitranslmed.3008002

Article  CAS  PubMed  Google Scholar 

Martella S, Lucas M, Porcu M, Perra L, Denaro N, Pretta A et al (2023) Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects. Semin Oncol 50(6):144–148. https://doi.org/10.1053/j.seminoncol.2023.11.003

Article  CAS  PubMed  Google Scholar 

Kotwal A, Haddox C, Block M, Kudva YC (2019) Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res Care 7(1):e000591. https://doi.org/10.1136/bmjdrc-2018-000591

Article  PubMed Central  PubMed  Google Scholar 

Barnabei A, Strigari L, Corsello A, Paragliola RM, Falzone L, Salvatori R et al (2022) Immune checkpoint Inhibitor-Induced central diabetes insipidus: looking for the needle in the haystack or a very rare Side-Effect to promptly diagnose?? Front Oncol 12:798517. https://doi.org/10.3389/fonc.2022.798517

Article  PubMed Central  CAS  PubMed  Google Scholar 

Shi Y, Shen M, Zheng X, Chen Y, Zhao R, Gu Y et al (2020) ICPis-Induced autoimmune polyendocrine syndrome type 2: A review of the literature and a protocol for optimal management. J Clin Endocrinol Metab 105(12). https://doi.org/10.1210/clinem/dgaa553

Piranavan P, Li Y, Brown E, Kemp EH, Trivedi N (2019) Immune checkpoint Inhibitor-Induced hypoparathyroidism associated with Calcium-Sensing Receptor-Activating autoantibodies. J Clin Endocrinol Metab 104(2):550–556. https://doi.org/10.1210/jc.2018-01151

Article  PubMed  Google Scholar 

Trinh B, Sanchez GO, Herzig P, Läubli H (2019) Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint Blockade for melanoma. J Immunother Cancer 7(1):52. https://doi.org/10.1186/s40425-019-0528-x

Article  PubMed Central  PubMed  Google Scholar 

El Kawkgi OM, Li D, Kotwal A, Wermers RA (2020) Hypoparathyroidism: an uncommon complication associated with immune checkpoint inhibitor therapy. Mayo Clin Proc Innov Qual Outcomes 4(6):821–825. https://doi.org/10.1016/j.mayocpiqo.2020.07.006

Article  PubMed Central  PubMed  Google Scholar 

Bai X, Lin X, Zheng K, Chen X, Wu X, Huang Y et al (2020) Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database. VigiBase Endocr 69(3):670–681. https://doi.org/10.1007/s12020-020-02355-9

Article  CAS  Google Scholar 

Muir CA, Wood CCG, Clifton-Bligh RJ, Long GV, Scolyer RA, Carlino MS et al (2022) Association of antithyroid antibodies in checkpoint Inhibitor-Associated thyroid Immune-Related adverse events. J Clin Endocrinol Metab 107(5):e1843–e9. https://doi.org/10.1210/clinem/dgac059

Article  PubMed  Google Scholar 

Muir CA, Tsang VHM, Menzies AM, Clifton-Bligh RJ (2022) Immune related adverse events of the Thyroid - A narrative review. Front Endocrinol (Lausanne) 13:886930. https://doi.org/10.3389/fendo.2022.886930

Article  PubMed  Google Scholar 

Muir CA, Menzies AM, Clifton-Bligh R, Tsang VHM (2020) Thyroid toxicity following immune checkpoint inhibitor treatment in advanced Cancer. Thyroid 30(10):1458–1469. https://doi.org/10.1089/thy.2020.0032

Article  CAS  PubMed  Google Scholar 

Kobayashi T, Iwama S, Yamagami A, Izuchi T, Suzuki K, Otake K et al (2024) Combined use of tyrosine kinase inhibitors with PD-(L)1 Blockade increased the risk of thyroid dysfunction in PD-(L)1 Blockade: a prospective study. Cancer Immunol Immunother 73(8):146. https://doi.org/10.1007/s00262-024-03733-2

Article  PubMed Central  CAS  PubMed  Google Scholar 

Tsai K, Ma H, Liang TZ, Xing Y, Chung S, Dorff T et al (2024) The combined effect of immune checkpoint inhibitors and tyrosine kinase inhibitors on thyroid function. Thyroid 34(2):158–166. https://doi.org/10.1089/thy.2023.0542

Article  PubMed Central  CAS  PubMed  Google Scholar 

Iyer PC, Cabanillas ME, Waguespack SG, Hu MI, Thosani S, Lavis VR et al (2018) Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. Thyroid.28(10):1243-51. https://doi.org/10.1089/thy.2018.0116

Gan EH, Mitchell AL, Plummer R, Pearce S, Perros P (2017) Tremelimumab-Induced graves hyperthyroidism. Eur Thyroid J 6(3):167–170. https://doi.org/10.1159/000464285

Article  PubMed Central  CAS  PubMed